{
 "disease": "merkel-cell-carcinoma",
 "label": "Merkel cell carcinoma",
 "url": "https://usebiotransfer.org/disease/merkel-cell-carcinoma/",
 "built": "2026-09-17",
 "facts_hash": {
  "answers": "a9941667bb9d",
  "targets": "cbfbd6952f5d"
 },
 "sources": {
  "targets": "Open Targets Platform GraphQL API v4",
  "trials": "ClinicalTrials.gov API v2"
 },
 "retrieved": {
  "targets": "2026-09-17",
  "trials": "2026-09-17"
 },
 "query": {
  "endpoint": "https://clinicaltrials.gov/api/v2/studies",
  "shape": "query.cond=<disease>&query.intr=<term>&pageSize=200",
  "active_statuses": [
   "ACTIVE_NOT_RECRUITING",
   "ENROLLING_BY_INVITATION",
   "NOT_YET_RECRUITING",
   "RECRUITING"
  ],
  "dedup": "by NCT id across synonyms",
  "study_types": "interventional counted in headline; observational reported separately",
  "known_floor": "trials naming an antigen only by product code are not retrieved by an intervention-name search"
 },
 "targets": [
  {
   "symbol": "TP53",
   "ensembl": "ENSG00000141510",
   "n_drug_entries": 9,
   "n_distinct_drugs": 8,
   "drugs": {
    "ALRIZOMADLIN": "PHASE_2",
    "CENERSEN": "PHASE_2",
    "CONTUSUGENE LADENOVEC": "PHASE_3",
    "EPRENETAPOPT": "PHASE_3",
    "IDASANUTLIN": "PHASE_3",
    "NAVTEMADLIN": "PHASE_3",
    "SIREMADLIN": "PHASE_2",
    "TEPRASIRAN": "PHASE_3"
   },
   "approved": [],
   "n_approved": 0,
   "approved_for": {},
   "tractability": [
    {
     "modality": "SM",
     "bucket": "Advanced Clinical"
    },
    {
     "modality": "SM",
     "bucket": "Structure with Ligand"
    },
    {
     "modality": "SM",
     "bucket": "High-Quality Ligand"
    },
    {
     "modality": "SM",
     "bucket": "Med-Quality Pocket"
    },
    {
     "modality": "SM",
     "bucket": "Druggable Family"
    },
    {
     "modality": "PR",
     "bucket": "UniProt Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Database Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Small Molecule Binder"
    },
    {
     "modality": "OC",
     "bucket": "Advanced Clinical"
    }
   ]
  },
  {
   "symbol": "RB1",
   "ensembl": "ENSG00000139687",
   "n_drug_entries": 0,
   "n_distinct_drugs": 0,
   "drugs": {},
   "approved": [],
   "n_approved": 0,
   "approved_for": {},
   "tractability": [
    {
     "modality": "SM",
     "bucket": "High-Quality Ligand"
    },
    {
     "modality": "SM",
     "bucket": "Med-Quality Pocket"
    },
    {
     "modality": "SM",
     "bucket": "Druggable Family"
    },
    {
     "modality": "PR",
     "bucket": "Database Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Half-life Data"
    },
    {
     "modality": "PR",
     "bucket": "Small Molecule Binder"
    }
   ]
  },
  {
   "symbol": "CD274",
   "ensembl": "ENSG00000120217",
   "n_drug_entries": 13,
   "n_distinct_drugs": 13,
   "drugs": {
    "ADEBRELIMAB": "PHASE_3",
    "ATEZOLIZUMAB": "APPROVAL",
    "AVELUMAB": "APPROVAL",
    "BINTRAFUSP ALFA": "PHASE_3",
    "COSIBELIMAB": "APPROVAL",
    "DANBURSTOTUG": "PHASE_2",
    "DURVALUMAB": "APPROVAL",
    "ENVAFOLIMAB": "PHASE_3",
    "ERFONRILIMAB": "PHASE_3",
    "INCB-086550": "PHASE_2",
    "PACMILIMAB": "PHASE_2",
    "SOCAZOLIMAB": "PHASE_3",
    "SUGEMALIMAB": "APPROVAL"
   },
   "approved": [
    "ATEZOLIZUMAB",
    "AVELUMAB",
    "COSIBELIMAB",
    "DURVALUMAB",
    "SUGEMALIMAB"
   ],
   "n_approved": 5,
   "approved_for": {
    "ATEZOLIZUMAB": [
     "urothelial carcinoma",
     "non-small cell lung carcinoma",
     "breast cancer",
     "small cell lung carcinoma",
     "breast neoplasm",
     "transitional cell carcinoma"
    ],
    "AVELUMAB": [
     "Merkel cell skin cancer",
     "urothelial carcinoma",
     "neuroendocrine neoplasm"
    ],
    "COSIBELIMAB": [
     "head and neck squamous cell carcinoma"
    ],
    "DURVALUMAB": [
     "non-small cell lung carcinoma",
     "small cell lung carcinoma",
     "urothelial carcinoma",
     "hepatocellular carcinoma"
    ],
    "SUGEMALIMAB": [
     "non-small cell lung carcinoma"
    ]
   },
   "tractability": [
    {
     "modality": "SM",
     "bucket": "Structure with Ligand"
    },
    {
     "modality": "SM",
     "bucket": "High-Quality Ligand"
    },
    {
     "modality": "SM",
     "bucket": "Med-Quality Pocket"
    },
    {
     "modality": "AB",
     "bucket": "Approved Drug"
    },
    {
     "modality": "AB",
     "bucket": "UniProt loc high conf"
    },
    {
     "modality": "AB",
     "bucket": "GO CC high conf"
    },
    {
     "modality": "AB",
     "bucket": "UniProt SigP or TMHMM"
    },
    {
     "modality": "PR",
     "bucket": "Literature"
    },
    {
     "modality": "PR",
     "bucket": "UniProt Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Small Molecule Binder"
    },
    {
     "modality": "OC",
     "bucket": "Advanced Clinical"
    }
   ]
  },
  {
   "symbol": "PDCD1",
   "ensembl": "ENSG00000188389",
   "n_drug_entries": 26,
   "n_distinct_drugs": 26,
   "drugs": {
    "APL-501": "PHASE_2",
    "BALSTILIMAB": "PHASE_3",
    "BUDIGALIMAB": "PHASE_2_3",
    "CADONILIMAB": "PHASE_3",
    "CAMRELIZUMAB": "PHASE_3",
    "CEMIPLIMAB": "APPROVAL",
    "CETRELIMAB": "PHASE_3",
    "CS-1003": "PHASE_3",
    "DOSTARLIMAB": "APPROVAL",
    "FINOTONLIMAB": "PHASE_3",
    "LOMVASTOMIG": "PHASE_2",
    "NIVOLUMAB": "APPROVAL",
    "PEMBROLIZUMAB": "APPROVAL",
    "PENPULIMAB": "PHASE_3",
    "PIDILIZUMAB": "PHASE_2",
    "PIMIVALIMAB": "PHASE_2",
    "PUCOTENLIMAB": "PHASE_3",
    "RETIFANLIMAB": "APPROVAL",
    "SASANLIMAB": "PHASE_3",
    "SERPLULIMAB": "APPROVAL",
    "SINTILIMAB": "APPROVAL",
    "SPARTALIZUMAB": "PHASE_3",
    "TEBOTELIMAB": "PHASE_2_3",
    "TISLELIZUMAB": "APPROVAL",
    "TORIPALIMAB": "APPROVAL",
    "ZIMBERELIMAB": "PHASE_3"
   },
   "approved": [
    "CEMIPLIMAB",
    "DOSTARLIMAB",
    "NIVOLUMAB",
    "PEMBROLIZUMAB",
    "RETIFANLIMAB",
    "SERPLULIMAB",
    "SINTILIMAB",
    "TISLELIZUMAB",
    "TORIPALIMAB"
   ],
   "n_approved": 9,
   "approved_for": {
    "CEMIPLIMAB": [
     "squamous cell carcinoma",
     "basal cell carcinoma",
     "cutaneous squamous cell carcinoma",
     "cervical cancer"
    ],
    "DOSTARLIMAB": [
     "endometrial cancer",
     "endometrial neoplasm"
    ],
    "NIVOLUMAB": [
     "head and neck cancer",
     "pleural mesothelioma",
     "gastric cancer",
     "melanoma",
     "non-small cell lung carcinoma",
     "renal cell carcinoma",
     "transitional cell carcinoma",
     "colorectal neoplasm",
     "Hodgkins lymphoma",
     "mesothelioma",
     "head and neck squamous cell carcinoma",
     "classic Hodgkin lymphoma",
     "metastatic melanoma"
    ],
    "PEMBROLIZUMAB": [
     "melanoma",
     "metastatic melanoma",
     "endometrium neoplasm",
     "head and neck squamous cell carcinoma",
     "transitional cell carcinoma",
     "renal cell carcinoma",
     "Hodgkins lymphoma",
     "non-small cell lung carcinoma"
    ],
    "RETIFANLIMAB": [
     "neuroendocrine carcinoma",
     "Merkel cell skin cancer",
     "squamous cell carcinoma"
    ],
    "SERPLULIMAB": [
     "esophageal squamous cell carcinoma",
     "non-small cell lung carcinoma",
     "small cell lung carcinoma"
    ],
    "SINTILIMAB": [
     "Hodgkins lymphoma"
    ],
    "TISLELIZUMAB": [
     "esophageal cancer",
     "Hodgkins lymphoma",
     "non-small cell lung carcinoma",
     "adenocarcinoma",
     "esophageal squamous cell carcinoma",
     "gastric neoplasm"
    ],
    "TORIPALIMAB": [
     "melanoma",
     "nasopharyngeal carcinoma",
     "urothelial carcinoma",
     "esophageal squamous cell carcinoma",
     "Niemann-Pick disease type B"
    ]
   },
   "tractability": [
    {
     "modality": "SM",
     "bucket": "Structure with Ligand"
    },
    {
     "modality": "SM",
     "bucket": "High-Quality Ligand"
    },
    {
     "modality": "AB",
     "bucket": "Approved Drug"
    },
    {
     "modality": "AB",
     "bucket": "UniProt loc high conf"
    },
    {
     "modality": "AB",
     "bucket": "GO CC high conf"
    },
    {
     "modality": "AB",
     "bucket": "UniProt SigP or TMHMM"
    },
    {
     "modality": "PR",
     "bucket": "Literature"
    },
    {
     "modality": "PR",
     "bucket": "UniProt Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Small Molecule Binder"
    },
    {
     "modality": "OC",
     "bucket": "Advanced Clinical"
    }
   ]
  },
  {
   "symbol": "PIK3CA",
   "ensembl": "ENSG00000121879",
   "n_drug_entries": 32,
   "n_distinct_drugs": 31,
   "drugs": {
    "ALPELISIB": "APPROVAL",
    "APITOLISIB": "PHASE_2",
    "AZD-6482": "UNKNOWN",
    "BAY-1082439": "PHASE_1",
    "BGT-226": "PHASE_1_2",
    "BUPARLISIB": "PHASE_3",
    "COPANLISIB": "APPROVAL",
    "DACTOLISIB": "PHASE_3",
    "DS-7423": "PHASE_1",
    "FIMEPINOSTAT": "PHASE_2",
    "GEDATOLISIB": "PHASE_3",
    "GSK-1059615": "PHASE_1",
    "INAVOLISIB": "APPROVAL",
    "IZORLISIB": "PHASE_1_2",
    "OMIPALISIB": "PHASE_1",
    "PANULISIB": "PHASE_1",
    "PAXALISIB": "PHASE_2_3",
    "PF-04691502": "PHASE_2",
    "PICTILISIB": "PHASE_2",
    "PILARALISIB": "PHASE_2",
    "PKI-179": "PHASE_1",
    "RECILISIB": "PHASE_1",
    "SAMOTOLISIB": "PHASE_2",
    "SERABELISIB": "PHASE_2",
    "SF-1126": "PHASE_2",
    "SONOLISIB": "PHASE_2",
    "TASELISIB": "PHASE_3",
    "VOXTALISIB": "PHASE_2",
    "VS-5584": "PHASE_1",
    "WX-037": "PHASE_1",
    "ZSTK-474": "PHASE_1"
   },
   "approved": [
    "ALPELISIB",
    "COPANLISIB",
    "INAVOLISIB"
   ],
   "n_approved": 3,
   "approved_for": {
    "ALPELISIB": [
     "breast cancer",
     "breast neoplasm",
     "breast carcinoma"
    ],
    "COPANLISIB": [
     "follicular lymphoma",
     "non-Hodgkin lymphoma",
     "neoplasm of mature B-cells"
    ],
    "INAVOLISIB": [
     "breast neoplasm"
    ]
   },
   "tractability": [
    {
     "modality": "SM",
     "bucket": "Approved Drug"
    },
    {
     "modality": "SM",
     "bucket": "Structure with Ligand"
    },
    {
     "modality": "SM",
     "bucket": "High-Quality Ligand"
    },
    {
     "modality": "SM",
     "bucket": "High-Quality Pocket"
    },
    {
     "modality": "SM",
     "bucket": "Druggable Family"
    },
    {
     "modality": "AB",
     "bucket": "GO CC med conf"
    },
    {
     "modality": "PR",
     "bucket": "Literature"
    },
    {
     "modality": "PR",
     "bucket": "Database Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Half-life Data"
    },
    {
     "modality": "PR",
     "bucket": "Small Molecule Binder"
    }
   ]
  },
  {
   "symbol": "NOTCH1",
   "ensembl": "ENSG00000148400",
   "n_drug_entries": 1,
   "n_distinct_drugs": 1,
   "drugs": {
    "BRONTICTUZUMAB": "PHASE_1"
   },
   "approved": [],
   "n_approved": 0,
   "approved_for": {},
   "tractability": [
    {
     "modality": "SM",
     "bucket": "Structure with Ligand"
    },
    {
     "modality": "SM",
     "bucket": "High-Quality Ligand"
    },
    {
     "modality": "SM",
     "bucket": "Med-Quality Pocket"
    },
    {
     "modality": "SM",
     "bucket": "Druggable Family"
    },
    {
     "modality": "AB",
     "bucket": "Advanced Clinical"
    },
    {
     "modality": "AB",
     "bucket": "GO CC high conf"
    },
    {
     "modality": "AB",
     "bucket": "UniProt loc med conf"
    },
    {
     "modality": "AB",
     "bucket": "UniProt SigP or TMHMM"
    },
    {
     "modality": "PR",
     "bucket": "UniProt Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Database Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Half-life Data"
    },
    {
     "modality": "PR",
     "bucket": "Small Molecule Binder"
    }
   ]
  },
  {
   "symbol": "KMT2D",
   "ensembl": "ENSG00000167548",
   "n_drug_entries": 0,
   "n_distinct_drugs": 0,
   "drugs": {},
   "approved": [],
   "n_approved": 0,
   "approved_for": {},
   "tractability": [
    {
     "modality": "SM",
     "bucket": "Structure with Ligand"
    },
    {
     "modality": "AB",
     "bucket": "Human Protein Atlas loc"
    },
    {
     "modality": "PR",
     "bucket": "UniProt Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Database Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Half-life Data"
    }
   ]
  },
  {
   "symbol": "MYCL",
   "ensembl": "ENSG00000116990",
   "n_drug_entries": 0,
   "n_distinct_drugs": 0,
   "drugs": {},
   "approved": [],
   "n_approved": 0,
   "approved_for": {},
   "tractability": []
  },
  {
   "symbol": "ATOH1",
   "ensembl": "ENSG00000172238",
   "n_drug_entries": 0,
   "n_distinct_drugs": 0,
   "drugs": {},
   "approved": [],
   "n_approved": 0,
   "approved_for": {},
   "tractability": []
  },
  {
   "symbol": "SOX2",
   "ensembl": "ENSG00000181449",
   "n_drug_entries": 0,
   "n_distinct_drugs": 0,
   "drugs": {},
   "approved": [],
   "n_approved": 0,
   "approved_for": {},
   "tractability": [
    {
     "modality": "SM",
     "bucket": "Structure with Ligand"
    },
    {
     "modality": "PR",
     "bucket": "UniProt Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Database Ubiquitination"
    }
   ]
  },
  {
   "symbol": "NCAM1",
   "ensembl": "ENSG00000149294",
   "n_drug_entries": 2,
   "n_distinct_drugs": 2,
   "drugs": {
    "LORVOTUZUMAB MERTANSINE": "PHASE_2",
    "ONCOLYSIN S": "PHASE_2"
   },
   "approved": [],
   "n_approved": 0,
   "approved_for": {},
   "tractability": [
    {
     "modality": "SM",
     "bucket": "High-Quality Pocket"
    },
    {
     "modality": "AB",
     "bucket": "Advanced Clinical"
    },
    {
     "modality": "AB",
     "bucket": "UniProt loc high conf"
    },
    {
     "modality": "AB",
     "bucket": "GO CC high conf"
    },
    {
     "modality": "AB",
     "bucket": "UniProt loc med conf"
    },
    {
     "modality": "AB",
     "bucket": "UniProt SigP or TMHMM"
    },
    {
     "modality": "AB",
     "bucket": "Human Protein Atlas loc"
    },
    {
     "modality": "PR",
     "bucket": "Database Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Half-life Data"
    },
    {
     "modality": "OC",
     "bucket": "Advanced Clinical"
    }
   ]
  },
  {
   "symbol": "LAG3",
   "ensembl": "ENSG00000089692",
   "n_drug_entries": 6,
   "n_distinct_drugs": 6,
   "drugs": {
    "EFTILAGIMOD ALFA": "PHASE_3",
    "FAVEZELIMAB": "PHASE_3",
    "FIANLIMAB": "PHASE_3",
    "IERAMILIMAB": "PHASE_2",
    "RELATLIMAB": "APPROVAL",
    "TEBOTELIMAB": "PHASE_2_3"
   },
   "approved": [
    "RELATLIMAB"
   ],
   "n_approved": 1,
   "approved_for": {
    "RELATLIMAB": [
     "melanoma"
    ]
   },
   "tractability": [
    {
     "modality": "AB",
     "bucket": "Approved Drug"
    },
    {
     "modality": "AB",
     "bucket": "UniProt loc high conf"
    },
    {
     "modality": "AB",
     "bucket": "GO CC high conf"
    },
    {
     "modality": "AB",
     "bucket": "UniProt loc med conf"
    },
    {
     "modality": "AB",
     "bucket": "UniProt SigP or TMHMM"
    },
    {
     "modality": "OC",
     "bucket": "Advanced Clinical"
    }
   ]
  }
 ],
 "trials": {
  "by_antigen": {
   "PD-L1": {
    "n": 43,
    "n_observational": 1,
    "n_active": 14,
    "n_withdrawn": 2,
    "trials": [
     {
      "nct": "NCT05267626",
      "title": "Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2R\u03b1 Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer",
      "status": "RECRUITING",
      "last_update": "2026-07-30",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06047379",
      "title": "Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis",
      "status": "RECRUITING",
      "last_update": "2026-09-15",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06444815",
      "title": "A Study of VET3-TGI in Patients With Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2026-04-07",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02155647",
      "title": "Avelumab in Participants With Merkel Cell Carcinoma (JAVELIN Merkel 200)",
      "status": "COMPLETED",
      "last_update": "2024-03-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02584829",
      "title": "Localized Radiation Therapy or Recombinant Interferon Beta and Avelumab With or Without Cellular Adoptive Immunotherapy in Treating Patients With Metastatic Merkel Cell Carcinoma",
      "status": "TERMINATED",
      "last_update": "2022-03-22",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02643303",
      "title": "A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible Cancers",
      "status": "COMPLETED",
      "last_update": "2022-12-02",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02890368",
      "title": "Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis Fungoides",
      "status": "TERMINATED",
      "last_update": "2023-04-05",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03074513",
      "title": "Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-09-14",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03126110",
      "title": "Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies",
      "status": "COMPLETED",
      "last_update": "2025-08-14",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03167164",
      "title": "QUILT-3.045: NANT Merkel Cell Carcinoma (MCC) Vaccine: Combination Immunotherapy in Subjects With MCC Who Have Progressed on or After PD-L1 Therapy",
      "status": "WITHDRAWN",
      "last_update": "2025-02-21",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03212404",
      "title": "Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-02-03",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03228667",
      "title": "QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-01-14",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03241173",
      "title": "A Study Exploring the Safety and Efficacy of INCAGN01949 in Combination With Immune Therapies in Advanced or Metastatic Malignancies",
      "status": "COMPLETED",
      "last_update": "2022-09-27",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03271372",
      "title": "Adjuvant Avelumab in Merkel Cell Cancer",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-06-15",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03544723",
      "title": "Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors.",
      "status": "UNKNOWN",
      "last_update": "2020-06-09",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03684785",
      "title": "Intratumoral Cavrotolimod Combined With Pembrolizumab or Cemiplimab in Patients With Merkel Cell Carcinoma, Cutaneous Squamous Cell Carcinoma, or Other Advanced Solid Tumors",
      "status": "TERMINATED",
      "last_update": "2022-04-07",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03747484",
      "title": "Gene-Modified Immune Cells (FH-MCVA2TCR) in Treating Patients With Metastatic or Unresectable Merkel Cell Cancer",
      "status": "TERMINATED",
      "last_update": "2025-03-06",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03783078",
      "title": "Pembrolizumab (MK-3475) as First-line Therapy for Advanced Merkel Cell Carcinoma (MK-3475-913)",
      "status": "COMPLETED",
      "last_update": "2025-05-28",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03787602",
      "title": "Navtemadlin (KRT-232) With or Without Anti-PD-1/Anti-PD-L1 for the Treatment of Patients With Merkel Cell Carcinoma",
      "status": "UNKNOWN",
      "last_update": "2023-03-02",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03841110",
      "title": "FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2023-05-01",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03853317",
      "title": "QUILT-3.063: A Study of N-803, haNK and Avelumab in Patients With Merkel Cell Carcinoma That Has Progressed After Checkpoint Therapy",
      "status": "TERMINATED",
      "last_update": "2024-08-09",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03901573",
      "title": "High-Risk Skin Cancers With Atezolizumab Plus NT-I7",
      "status": "TERMINATED",
      "last_update": "2025-10-22",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03988647",
      "title": "Palliative RT & Anti-PD-1/PD-L1 Checkpoint Blockade in Metastatic Merkel Cell Carcinoma",
      "status": "TERMINATED",
      "last_update": "2021-08-09",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04116320",
      "title": "Focused Ultrasound Ablation and PD-1 Antibody Blockade in Advanced Solid Tumors",
      "status": "TERMINATED",
      "last_update": "2025-07-14",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04157985",
      "title": "Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2025-12-11",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04260802",
      "title": "A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers",
      "status": "TERMINATED",
      "last_update": "2026-01-12",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04261855",
      "title": "Targeted Therapy and Avelumab in Merkel Cell Carcinoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-03-27",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04291885",
      "title": "Immunotherapy Adjuvant Trial in Patients With Stage I-III Merkel Cell Carcinoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-04-09",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04393753",
      "title": "Domatinostat in Combination With Avelumab in Patients With Advanced Merkel Cell Carcinoma Progressing on Anti-PD-(L)1",
      "status": "COMPLETED",
      "last_update": "2024-05-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04458259",
      "title": "Study of PF-07265807 in Participants With Metastatic Solid Tumors.",
      "status": "TERMINATED",
      "last_update": "2026-06-04",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04551885",
      "title": "FT516 in Combination With Monoclonal Antibodies in Advanced Solid Tumors",
      "status": "TERMINATED",
      "last_update": "2023-09-21",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04590781",
      "title": "Safety and Efficacy of XmAb18087 \u00b1 Pembrolizumab in Advanced Merkel Cell Carcinoma or Extensive-stage Small Cell Lung Cancer",
      "status": "TERMINATED",
      "last_update": "2023-04-20",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04792073",
      "title": "Study of Avelumab and/or Radiation Therapy in People With Advanced Merkel Cell Carcinoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-04-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04874831",
      "title": "Domatinostat in Combination With Avelumab in Patients With Treatment-na\u00efve Metastatic Merkel Cell Carcinoma (MERKLIN 1)",
      "status": "WITHDRAWN",
      "last_update": "2021-11-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04902040",
      "title": "Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies",
      "status": "TERMINATED",
      "last_update": "2026-04-30",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04916002",
      "title": "A Trial To Find Out If Vidutolimod Together With Cemiplimab Is Safe And If It Works In Adult Participants With Advanced Cancer Or Metastatic Cancer",
      "status": "TERMINATED",
      "last_update": "2026-06-09",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05069935",
      "title": "FT538 in Combination With Monoclonal Antibodies in Advanced Solid Tumors",
      "status": "TERMINATED",
      "last_update": "2023-09-21",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05358938",
      "title": "Exercise to Boost Response to Checkpoint Blockade Immunotherapy",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-09-15",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05429866",
      "title": "Immunological Variables Associated to ICI Toxicity in Cancer Patients",
      "status": "UNKNOWN",
      "last_update": "2023-03-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05947500",
      "title": "Testing the Combination of Two Anticancer Drugs M1774 (Tuvusertib) and Avelumab to Evaluate Their Safety and Effectiveness in Treating Merkel Cell Skin Cancer, MATRiX Trial",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-31",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06056895",
      "title": "Triple Immune Checkpoint Inhibition for Advanced or Metastatic PD-(L)1 Refractory Merkel Cell Carcinoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06939036",
      "title": "Study of 225Ac-SS0110 in Subjects With ES-SCLC or MCC (SANTANA-225 )",
      "status": "TERMINATED",
      "last_update": "2026-02-05",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07472322",
      "title": "ASTX727 & Retifanlimab-dlwr for Advanced Merkel Cell After Progression on Anti-PD-(L)1",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-09-02",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ],
    "cell_therapy": {
     "n": 2,
     "n_observational": 0,
     "n_active": 0,
     "n_withdrawn": 0,
     "trials": [
      {
       "nct": "NCT02584829",
       "title": "Localized Radiation Therapy or Recombinant Interferon Beta and Avelumab With or Without Cellular Adoptive Immunotherapy in Treating Patients With Metastatic Merkel Cell Carcinoma",
       "status": "TERMINATED",
       "last_update": "2022-03-22",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT03747484",
       "title": "Gene-Modified Immune Cells (FH-MCVA2TCR) in Treating Patients With Metastatic or Unresectable Merkel Cell Cancer",
       "status": "TERMINATED",
       "last_update": "2025-03-06",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      }
     ]
    },
    "synonyms_searched": [
     "PD-L1",
     "avelumab",
     "Bavencio",
     "atezolizumab",
     "durvalumab"
    ]
   },
   "PD-1": {
    "n": 69,
    "n_observational": 0,
    "n_active": 32,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT04975152",
      "title": "Neoadjuvant Cemiplimab in Newly Diagnosed or Recurrent Stage I-II Merkel Cell Carcinoma and Locoregionally Advanced Cutaneous Squamous Cell Carcinoma",
      "status": "RECRUITING",
      "last_update": "2026-06-25",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05076760",
      "title": "MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2026-06-11",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05086692",
      "title": "A Beta-only IL-2 ImmunoTherapY Study",
      "status": "RECRUITING",
      "last_update": "2025-07-09",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05267626",
      "title": "Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2R\u03b1 Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer",
      "status": "RECRUITING",
      "last_update": "2026-07-30",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05269381",
      "title": "Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2026-08-20",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05496036",
      "title": "Neoadjuvant PD-1 Blockade in Resectable Merkel Cell Carcinoma",
      "status": "RECRUITING",
      "last_update": "2026-02-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05583708",
      "title": "Phase II Study of Peptide Receptor Radionuclide Therapy in Combination With Immunotherapy for Patients With Merkel Cell Cancer",
      "status": "RECRUITING",
      "last_update": "2026-04-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05859074",
      "title": "A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer",
      "status": "RECRUITING",
      "last_update": "2026-08-12",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05896839",
      "title": "Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer",
      "status": "RECRUITING",
      "last_update": "2026-08-31",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06047379",
      "title": "Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis",
      "status": "RECRUITING",
      "last_update": "2026-09-15",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06151236",
      "title": "Neoadjuvant Nivolumab and Relatlimab in Merkel Cell Carcinoma",
      "status": "RECRUITING",
      "last_update": "2026-02-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06940440",
      "title": "IFx-Hu2.0 As An Adjunctive Therapy To Pembrolizumab In Advanced Or Metastatic Merkel Cell Carcinoma (MCC)",
      "status": "RECRUITING",
      "last_update": "2025-10-15",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06947928",
      "title": "Placebo-Controlled Trial of IFx-Hu2.0 Followed By Pembrolizumab In Checkpoint Inhibitor Na\u00efve Participants With Advanced Or Metastatic Merkel Cell Carcinoma",
      "status": "RECRUITING",
      "last_update": "2026-04-17",
      "phase": "PHASE2/PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07115043",
      "title": "A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2026-08-19",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07302347",
      "title": "A Study of Pembrolizumab in Japanese Pediatric Participants With Solid Tumors or Lymphomas and Japanese Adult Participants With Merkel Cell Carcinoma (MK-3475-G21/KEYNOTE-G21)",
      "status": "RECRUITING",
      "last_update": "2026-07-13",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07387198",
      "title": "Neoadjuvant Merkel Cell Carcinoma Therapy (Tx) With the PD-1 Inhibitor Cemiplimab",
      "status": "RECRUITING",
      "last_update": "2026-06-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07749586",
      "title": "A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2026-08-06",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02196961",
      "title": "Adjuvant Therapy of Completely Resected Merkel Cell Carcinoma With Immune Checkpoint Blocking Antibodies vs Observation",
      "status": "COMPLETED",
      "last_update": "2025-04-09",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02267603",
      "title": "Pembrolizumab in Treating Patients With Advanced Merkel Cell Cancer",
      "status": "COMPLETED",
      "last_update": "2023-07-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02635672",
      "title": "Phase I Dose Escalation Study for VIP152 in Patients With Advanced Cancer",
      "status": "COMPLETED",
      "last_update": "2024-11-15",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02890368",
      "title": "Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis Fungoides",
      "status": "TERMINATED",
      "last_update": "2023-04-05",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02978625",
      "title": "Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03071406",
      "title": "Randomized Study of Nivolumab+Ipilimumab+/- SBRT for Metastatic Merkel Cell Carcinoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-03-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03126110",
      "title": "Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies",
      "status": "COMPLETED",
      "last_update": "2025-08-14",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03212404",
      "title": "Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-02-03",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03228667",
      "title": "QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-01-14",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03236935",
      "title": "Phase Ib of L-NMMA and Pembrolizumab",
      "status": "COMPLETED",
      "last_update": "2026-04-09",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03241173",
      "title": "A Study Exploring the Safety and Efficacy of INCAGN01949 in Combination With Immune Therapies in Advanced or Metastatic Malignancies",
      "status": "COMPLETED",
      "last_update": "2022-09-27",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03277352",
      "title": "INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies",
      "status": "TERMINATED",
      "last_update": "2021-07-22",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03304639",
      "title": "Testing the Addition of Radiation Therapy to Immunotherapy for Merkel Cell Carcinoma",
      "status": "COMPLETED",
      "last_update": "2026-08-25",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03435640",
      "title": "REVEAL Study of NKTR-262 in Combination With NKTR-214 and Nivolumab in Patients With Locally Advanced / Metastatic Solid Tumor Malignancies",
      "status": "TERMINATED",
      "last_update": "2023-03-08",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03544723",
      "title": "Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors.",
      "status": "UNKNOWN",
      "last_update": "2020-06-09",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03599713",
      "title": "A Study of INCMGA00012 in Metastatic Merkel Cell Carcinoma (POD1UM-201)",
      "status": "COMPLETED",
      "last_update": "2025-08-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03629756",
      "title": "A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies",
      "status": "COMPLETED",
      "last_update": "2024-05-24",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03684785",
      "title": "Intratumoral Cavrotolimod Combined With Pembrolizumab or Cemiplimab in Patients With Merkel Cell Carcinoma, Cutaneous Squamous Cell Carcinoma, or Other Advanced Solid Tumors",
      "status": "TERMINATED",
      "last_update": "2022-04-07",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03712605",
      "title": "Testing Pembrolizumab Versus Observation in Patients With Merkel Cell Carcinoma After Surgery, STAMP Trial",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-04",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03747484",
      "title": "Gene-Modified Immune Cells (FH-MCVA2TCR) in Treating Patients With Metastatic or Unresectable Merkel Cell Cancer",
      "status": "TERMINATED",
      "last_update": "2025-03-06",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03783078",
      "title": "Pembrolizumab (MK-3475) as First-line Therapy for Advanced Merkel Cell Carcinoma (MK-3475-913)",
      "status": "COMPLETED",
      "last_update": "2025-05-28",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03787602",
      "title": "Navtemadlin (KRT-232) With or Without Anti-PD-1/Anti-PD-L1 for the Treatment of Patients With Merkel Cell Carcinoma",
      "status": "UNKNOWN",
      "last_update": "2023-03-02",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03798639",
      "title": "Nivolumab and Radiation Therapy or Ipilimumab as Adjuvant Therapy in Treating Patients With Merkel Cell Cancer",
      "status": "COMPLETED",
      "last_update": "2024-04-12",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03816332",
      "title": "Tacrolimus, Nivolumab, and Ipilimumab in Treating Kidney Transplant Recipients With Selected Unresectable or Metastatic Cancers",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-31",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03841110",
      "title": "FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2023-05-01",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03901573",
      "title": "High-Risk Skin Cancers With Atezolizumab Plus NT-I7",
      "status": "TERMINATED",
      "last_update": "2025-10-22",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03988647",
      "title": "Palliative RT & Anti-PD-1/PD-L1 Checkpoint Blockade in Metastatic Merkel Cell Carcinoma",
      "status": "TERMINATED",
      "last_update": "2021-08-09",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04116320",
      "title": "Focused Ultrasound Ablation and PD-1 Antibody Blockade in Advanced Solid Tumors",
      "status": "TERMINATED",
      "last_update": "2025-07-14",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04157985",
      "title": "Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2025-12-11",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04187872",
      "title": "LITT and Pembrolizumab in Recurrent Brain Metastasis",
      "status": "TERMINATED",
      "last_update": "2023-12-27",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04234113",
      "title": "Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors",
      "status": "TERMINATED",
      "last_update": "2026-03-27",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04242199",
      "title": "Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2025-07-14",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04260802",
      "title": "A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers",
      "status": "TERMINATED",
      "last_update": "2026-01-12",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04272034",
      "title": "Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Advanced Solid Tumors",
      "status": "TERMINATED",
      "last_update": "2025-10-16",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04458259",
      "title": "Study of PF-07265807 in Participants With Metastatic Solid Tumors.",
      "status": "TERMINATED",
      "last_update": "2026-06-04",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04590781",
      "title": "Safety and Efficacy of XmAb18087 \u00b1 Pembrolizumab in Advanced Merkel Cell Carcinoma or Extensive-stage Small Cell Lung Cancer",
      "status": "TERMINATED",
      "last_update": "2023-04-20",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04616248",
      "title": "In Situ Immunomodulation With CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients w/ Unresectable and Metastatic Solid Tumors",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-06-18",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04725331",
      "title": "A Clinical Trial Assessing BT-001 Alone and in Combination With Pembrolizumab in Metastatic or Advanced Solid Tumors",
      "status": "TERMINATED",
      "last_update": "2025-11-21",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04869137",
      "title": "Neoadjuvant Lenvatinib Plus Pembrolizumab in Merkel Cell Carcinoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-04-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04902040",
      "title": "Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies",
      "status": "TERMINATED",
      "last_update": "2026-04-30",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04916002",
      "title": "A Trial To Find Out If Vidutolimod Together With Cemiplimab Is Safe And If It Works In Adult Participants With Advanced Cancer Or Metastatic Cancer",
      "status": "TERMINATED",
      "last_update": "2026-06-09",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05069935",
      "title": "FT538 in Combination With Monoclonal Antibodies in Advanced Solid Tumors",
      "status": "TERMINATED",
      "last_update": "2023-09-21",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05358938",
      "title": "Exercise to Boost Response to Checkpoint Blockade Immunotherapy",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-09-15",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05429866",
      "title": "Immunological Variables Associated to ICI Toxicity in Cancer Patients",
      "status": "UNKNOWN",
      "last_update": "2023-03-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05594290",
      "title": "Chemo-immunotherapy in Patients With Resectable Merkel Cell Carcinoma Prior to Surgery",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-01-14",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05864144",
      "title": "A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2026-09-02",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06014086",
      "title": "Intratumoral PH-762 for Cutaneous Carcinoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-02-11",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06056895",
      "title": "Triple Immune Checkpoint Inhibition for Advanced or Metastatic PD-(L)1 Refractory Merkel Cell Carcinoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06086288",
      "title": "Study of PembrolizumAb combiNeD With Cisplatin or carbOplatin and Etoposide in Treatment na\u00efve Advanced meRkel Cell cArcinoma (MCC)",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2023-10-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06939036",
      "title": "Study of 225Ac-SS0110 in Subjects With ES-SCLC or MCC (SANTANA-225 )",
      "status": "TERMINATED",
      "last_update": "2026-02-05",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07472322",
      "title": "ASTX727 & Retifanlimab-dlwr for Advanced Merkel Cell After Progression on Anti-PD-(L)1",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-09-02",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07576725",
      "title": "Low Dose, Reduced Frequency Nivolumab for the Treatment of Unresectable or Metastatic Cancer, AFFORD IO Trial",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-05-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ],
    "cell_therapy": {
     "n": 2,
     "n_observational": 0,
     "n_active": 0,
     "n_withdrawn": 0,
     "trials": [
      {
       "nct": "NCT03435640",
       "title": "REVEAL Study of NKTR-262 in Combination With NKTR-214 and Nivolumab in Patients With Locally Advanced / Metastatic Solid Tumor Malignancies",
       "status": "TERMINATED",
       "last_update": "2023-03-08",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT03747484",
       "title": "Gene-Modified Immune Cells (FH-MCVA2TCR) in Treating Patients With Metastatic or Unresectable Merkel Cell Cancer",
       "status": "TERMINATED",
       "last_update": "2025-03-06",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      }
     ]
    },
    "synonyms_searched": [
     "PD-1",
     "pembrolizumab",
     "Keytruda",
     "nivolumab",
     "retifanlimab",
     "Zynyz",
     "cemiplimab"
    ]
   },
   "CTLA-4": {
    "n": 12,
    "n_observational": 0,
    "n_active": 5,
    "n_withdrawn": 1,
    "trials": [
     {
      "nct": "NCT05896839",
      "title": "Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer",
      "status": "RECRUITING",
      "last_update": "2026-08-31",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06047379",
      "title": "Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis",
      "status": "RECRUITING",
      "last_update": "2026-09-15",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01913691",
      "title": "Study of the Drug Ipilimumab for Metastatic Merkel Cell Carcinoma",
      "status": "WITHDRAWN",
      "last_update": "2019-12-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02196961",
      "title": "Adjuvant Therapy of Completely Resected Merkel Cell Carcinoma With Immune Checkpoint Blocking Antibodies vs Observation",
      "status": "COMPLETED",
      "last_update": "2025-04-09",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02643303",
      "title": "A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible Cancers",
      "status": "COMPLETED",
      "last_update": "2022-12-02",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03071406",
      "title": "Randomized Study of Nivolumab+Ipilimumab+/- SBRT for Metastatic Merkel Cell Carcinoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-03-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03126110",
      "title": "Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies",
      "status": "COMPLETED",
      "last_update": "2025-08-14",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03241173",
      "title": "A Study Exploring the Safety and Efficacy of INCAGN01949 in Combination With Immune Therapies in Advanced or Metastatic Malignancies",
      "status": "COMPLETED",
      "last_update": "2022-09-27",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03798639",
      "title": "Nivolumab and Radiation Therapy or Ipilimumab as Adjuvant Therapy in Treating Patients With Merkel Cell Cancer",
      "status": "COMPLETED",
      "last_update": "2024-04-12",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03816332",
      "title": "Tacrolimus, Nivolumab, and Ipilimumab in Treating Kidney Transplant Recipients With Selected Unresectable or Metastatic Cancers",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-31",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04157985",
      "title": "Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2025-12-11",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05358938",
      "title": "Exercise to Boost Response to Checkpoint Blockade Immunotherapy",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-09-15",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     }
    ],
    "cell_therapy": {
     "n": 0,
     "n_observational": 0,
     "n_active": 0,
     "n_withdrawn": 0,
     "trials": []
    },
    "synonyms_searched": [
     "CTLA-4",
     "ipilimumab"
    ]
   },
   "polyomavirus T antigen": {
    "n": 12,
    "n_observational": 1,
    "n_active": 5,
    "n_withdrawn": 1,
    "trials": [
     {
      "nct": "NCT05592626",
      "title": "A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2026-08-11",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05896839",
      "title": "Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer",
      "status": "RECRUITING",
      "last_update": "2026-08-31",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06047379",
      "title": "Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis",
      "status": "RECRUITING",
      "last_update": "2026-09-15",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01758458",
      "title": "Viral Oncoprotein Targeted Autologous T Cell Therapy for Merkel Cell Carcinoma",
      "status": "TERMINATED",
      "last_update": "2017-04-19",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01913691",
      "title": "Study of the Drug Ipilimumab for Metastatic Merkel Cell Carcinoma",
      "status": "WITHDRAWN",
      "last_update": "2019-12-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02584829",
      "title": "Localized Radiation Therapy or Recombinant Interferon Beta and Avelumab With or Without Cellular Adoptive Immunotherapy in Treating Patients With Metastatic Merkel Cell Carcinoma",
      "status": "TERMINATED",
      "last_update": "2022-03-22",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02643303",
      "title": "A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible Cancers",
      "status": "COMPLETED",
      "last_update": "2022-12-02",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03747484",
      "title": "Gene-Modified Immune Cells (FH-MCVA2TCR) in Treating Patients With Metastatic or Unresectable Merkel Cell Cancer",
      "status": "TERMINATED",
      "last_update": "2025-03-06",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03798639",
      "title": "Nivolumab and Radiation Therapy or Ipilimumab as Adjuvant Therapy in Treating Patients With Merkel Cell Cancer",
      "status": "COMPLETED",
      "last_update": "2024-04-12",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03816332",
      "title": "Tacrolimus, Nivolumab, and Ipilimumab in Treating Kidney Transplant Recipients With Selected Unresectable or Metastatic Cancers",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-31",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04705389",
      "title": "SerUM Markers in MERkel Cell Carcinoma Patients: a Longitudinal moniTorIng Study for optiMization of European Guidelines",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-06-12",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05422781",
      "title": "Study To Evaluate The Safety, Tolerability And Immunogenicity Of 4 mg Of ITI-3000 In Patients With Polyomavirus-Positive Merkel Cell Carcinoma (MCC)",
      "status": "COMPLETED",
      "last_update": "2023-11-22",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     }
    ],
    "cell_therapy": {
     "n": 4,
     "n_observational": 0,
     "n_active": 1,
     "n_withdrawn": 0,
     "trials": [
      {
       "nct": "NCT05592626",
       "title": "A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors",
       "status": "RECRUITING",
       "last_update": "2026-08-11",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT01758458",
       "title": "Viral Oncoprotein Targeted Autologous T Cell Therapy for Merkel Cell Carcinoma",
       "status": "TERMINATED",
       "last_update": "2017-04-19",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT02584829",
       "title": "Localized Radiation Therapy or Recombinant Interferon Beta and Avelumab With or Without Cellular Adoptive Immunotherapy in Treating Patients With Metastatic Merkel Cell Carcinoma",
       "status": "TERMINATED",
       "last_update": "2022-03-22",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT03747484",
       "title": "Gene-Modified Immune Cells (FH-MCVA2TCR) in Treating Patients With Metastatic or Unresectable Merkel Cell Cancer",
       "status": "TERMINATED",
       "last_update": "2025-03-06",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      }
     ]
    },
    "synonyms_searched": [
     "T antigen",
     "MCPyV",
     "polyomavirus",
     "TCR-T",
     "T-cell receptor"
    ]
   },
   "oncolytic": {
    "n": 5,
    "n_observational": 0,
    "n_active": 2,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT02819843",
      "title": "A Study of T-VEC (Talimogene Laherparepvec) With or Without Radiotherapy for Melanoma, Merkel Cell Carcinoma, or Other Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2025-01-29",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02890368",
      "title": "Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis Fungoides",
      "status": "TERMINATED",
      "last_update": "2023-04-05",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02978625",
      "title": "Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03458117",
      "title": "T-VEC in Non-melanoma Skin Cancer",
      "status": "COMPLETED",
      "last_update": "2022-03-18",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04349436",
      "title": "Study to Investigate the Efficacy and Safety of RP1 in Adult Patients With Organ Transplants and Advanced Skin Malignancies",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-04-22",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ],
    "cell_therapy": {
     "n": 0,
     "n_observational": 0,
     "n_active": 0,
     "n_withdrawn": 0,
     "trials": []
    },
    "synonyms_searched": [
     "talimogene",
     "T-VEC",
     "RP1"
    ]
   },
   "somatostatin": {
    "n": 7,
    "n_observational": 0,
    "n_active": 2,
    "n_withdrawn": 1,
    "trials": [
     {
      "nct": "NCT05583708",
      "title": "Phase II Study of Peptide Receptor Radionuclide Therapy in Combination With Immunotherapy for Patients With Merkel Cell Cancer",
      "status": "RECRUITING",
      "last_update": "2026-04-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00002947",
      "title": "Indium In 111 Pentetreotide in Treating Patients With Refractory Cancer",
      "status": "TERMINATED",
      "last_update": "2014-07-02",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01204476",
      "title": "Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine Carcinoma",
      "status": "COMPLETED",
      "last_update": "2016-07-15",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02351128",
      "title": "Treatment of Unresecable and/or Metastatic Merkel Cell Carcinoma by Somatostatine Analogues",
      "status": "COMPLETED",
      "last_update": "2017-10-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04261855",
      "title": "Targeted Therapy and Avelumab in Merkel Cell Carcinoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-03-27",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04276597",
      "title": "Phase-II Study of Lu177DOTATOC in Adults With STTR(+)Pulmonary, Pheochromocytoma, Paraganglioma, Unknown Primary, Thymus NETs (PUTNET), or Any Other Non-.GEP-NET.",
      "status": "WITHDRAWN",
      "last_update": "2023-03-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06939036",
      "title": "Study of 225Ac-SS0110 in Subjects With ES-SCLC or MCC (SANTANA-225 )",
      "status": "TERMINATED",
      "last_update": "2026-02-05",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ],
    "cell_therapy": {
     "n": 0,
     "n_observational": 0,
     "n_active": 0,
     "n_withdrawn": 0,
     "trials": []
    },
    "synonyms_searched": [
     "somatostatin",
     "lutetium",
     "177Lu",
     "octreotide"
    ]
   },
   "LAG-3": {
    "n": 4,
    "n_observational": 0,
    "n_active": 3,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT06151236",
      "title": "Neoadjuvant Nivolumab and Relatlimab in Merkel Cell Carcinoma",
      "status": "RECRUITING",
      "last_update": "2026-02-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03538028",
      "title": "A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies",
      "status": "COMPLETED",
      "last_update": "2020-10-30",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05358938",
      "title": "Exercise to Boost Response to Checkpoint Blockade Immunotherapy",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-09-15",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06056895",
      "title": "Triple Immune Checkpoint Inhibition for Advanced or Metastatic PD-(L)1 Refractory Merkel Cell Carcinoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ],
    "cell_therapy": {
     "n": 0,
     "n_observational": 0,
     "n_active": 0,
     "n_withdrawn": 0,
     "trials": []
    },
    "synonyms_searched": [
     "LAG-3",
     "relatlimab"
    ]
   }
  },
  "by_drug": {
   "ATEZOLIZUMAB": {
    "n": 14,
    "n_observational": 0,
    "n_active": 4,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT06444815",
      "title": "A Study of VET3-TGI in Patients With Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2026-04-07",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02890368",
      "title": "Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis Fungoides",
      "status": "TERMINATED",
      "last_update": "2023-04-05",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03074513",
      "title": "Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-09-14",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03228667",
      "title": "QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-01-14",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03271372",
      "title": "Adjuvant Avelumab in Merkel Cell Cancer",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-06-15",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03544723",
      "title": "Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors.",
      "status": "UNKNOWN",
      "last_update": "2020-06-09",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03841110",
      "title": "FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2023-05-01",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03901573",
      "title": "High-Risk Skin Cancers With Atezolizumab Plus NT-I7",
      "status": "TERMINATED",
      "last_update": "2025-10-22",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04116320",
      "title": "Focused Ultrasound Ablation and PD-1 Antibody Blockade in Advanced Solid Tumors",
      "status": "TERMINATED",
      "last_update": "2025-07-14",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04157985",
      "title": "Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2025-12-11",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04902040",
      "title": "Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies",
      "status": "TERMINATED",
      "last_update": "2026-04-30",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05069935",
      "title": "FT538 in Combination With Monoclonal Antibodies in Advanced Solid Tumors",
      "status": "TERMINATED",
      "last_update": "2023-09-21",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05429866",
      "title": "Immunological Variables Associated to ICI Toxicity in Cancer Patients",
      "status": "UNKNOWN",
      "last_update": "2023-03-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06939036",
      "title": "Study of 225Ac-SS0110 in Subjects With ES-SCLC or MCC (SANTANA-225 )",
      "status": "TERMINATED",
      "last_update": "2026-02-05",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "AVELUMAB": {
    "n": 23,
    "n_observational": 1,
    "n_active": 8,
    "n_withdrawn": 2,
    "trials": [
     {
      "nct": "NCT05267626",
      "title": "Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2R\u03b1 Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer",
      "status": "RECRUITING",
      "last_update": "2026-07-30",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02155647",
      "title": "Avelumab in Participants With Merkel Cell Carcinoma (JAVELIN Merkel 200)",
      "status": "COMPLETED",
      "last_update": "2024-03-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02584829",
      "title": "Localized Radiation Therapy or Recombinant Interferon Beta and Avelumab With or Without Cellular Adoptive Immunotherapy in Treating Patients With Metastatic Merkel Cell Carcinoma",
      "status": "TERMINATED",
      "last_update": "2022-03-22",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02890368",
      "title": "Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis Fungoides",
      "status": "TERMINATED",
      "last_update": "2023-04-05",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03167164",
      "title": "QUILT-3.045: NANT Merkel Cell Carcinoma (MCC) Vaccine: Combination Immunotherapy in Subjects With MCC Who Have Progressed on or After PD-L1 Therapy",
      "status": "WITHDRAWN",
      "last_update": "2025-02-21",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03228667",
      "title": "QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-01-14",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03271372",
      "title": "Adjuvant Avelumab in Merkel Cell Cancer",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-06-15",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03747484",
      "title": "Gene-Modified Immune Cells (FH-MCVA2TCR) in Treating Patients With Metastatic or Unresectable Merkel Cell Cancer",
      "status": "TERMINATED",
      "last_update": "2025-03-06",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03787602",
      "title": "Navtemadlin (KRT-232) With or Without Anti-PD-1/Anti-PD-L1 for the Treatment of Patients With Merkel Cell Carcinoma",
      "status": "UNKNOWN",
      "last_update": "2023-03-02",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03853317",
      "title": "QUILT-3.063: A Study of N-803, haNK and Avelumab in Patients With Merkel Cell Carcinoma That Has Progressed After Checkpoint Therapy",
      "status": "TERMINATED",
      "last_update": "2024-08-09",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04260802",
      "title": "A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers",
      "status": "TERMINATED",
      "last_update": "2026-01-12",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04261855",
      "title": "Targeted Therapy and Avelumab in Merkel Cell Carcinoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-03-27",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04291885",
      "title": "Immunotherapy Adjuvant Trial in Patients With Stage I-III Merkel Cell Carcinoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-04-09",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04393753",
      "title": "Domatinostat in Combination With Avelumab in Patients With Advanced Merkel Cell Carcinoma Progressing on Anti-PD-(L)1",
      "status": "COMPLETED",
      "last_update": "2024-05-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04551885",
      "title": "FT516 in Combination With Monoclonal Antibodies in Advanced Solid Tumors",
      "status": "TERMINATED",
      "last_update": "2023-09-21",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04792073",
      "title": "Study of Avelumab and/or Radiation Therapy in People With Advanced Merkel Cell Carcinoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-04-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04874831",
      "title": "Domatinostat in Combination With Avelumab in Patients With Treatment-na\u00efve Metastatic Merkel Cell Carcinoma (MERKLIN 1)",
      "status": "WITHDRAWN",
      "last_update": "2021-11-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04902040",
      "title": "Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies",
      "status": "TERMINATED",
      "last_update": "2026-04-30",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05069935",
      "title": "FT538 in Combination With Monoclonal Antibodies in Advanced Solid Tumors",
      "status": "TERMINATED",
      "last_update": "2023-09-21",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05358938",
      "title": "Exercise to Boost Response to Checkpoint Blockade Immunotherapy",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-09-15",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05429866",
      "title": "Immunological Variables Associated to ICI Toxicity in Cancer Patients",
      "status": "UNKNOWN",
      "last_update": "2023-03-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05947500",
      "title": "Testing the Combination of Two Anticancer Drugs M1774 (Tuvusertib) and Avelumab to Evaluate Their Safety and Effectiveness in Treating Merkel Cell Skin Cancer, MATRiX Trial",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-31",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06939036",
      "title": "Study of 225Ac-SS0110 in Subjects With ES-SCLC or MCC (SANTANA-225 )",
      "status": "TERMINATED",
      "last_update": "2026-02-05",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "BUDIGALIMAB": {
    "n": 2,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT03000257",
      "title": "A Study of Budigalimab (ABBV-181) in Participants With Advanced Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2022-04-14",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03071757",
      "title": "A Study of the Safety, Tolerability and Pharmacokinetics of ABBV-368 as a Single Agent and Combination in Subjects With Locally Advanced or Metastatic Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2022-04-28",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "CEMIPLIMAB": {
    "n": 8,
    "n_observational": 0,
    "n_active": 3,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT04975152",
      "title": "Neoadjuvant Cemiplimab in Newly Diagnosed or Recurrent Stage I-II Merkel Cell Carcinoma and Locoregionally Advanced Cutaneous Squamous Cell Carcinoma",
      "status": "RECRUITING",
      "last_update": "2026-06-25",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07387198",
      "title": "Neoadjuvant Merkel Cell Carcinoma Therapy (Tx) With the PD-1 Inhibitor Cemiplimab",
      "status": "RECRUITING",
      "last_update": "2026-06-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03684785",
      "title": "Intratumoral Cavrotolimod Combined With Pembrolizumab or Cemiplimab in Patients With Merkel Cell Carcinoma, Cutaneous Squamous Cell Carcinoma, or Other Advanced Solid Tumors",
      "status": "TERMINATED",
      "last_update": "2022-04-07",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04157985",
      "title": "Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2025-12-11",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04916002",
      "title": "A Trial To Find Out If Vidutolimod Together With Cemiplimab Is Safe And If It Works In Adult Participants With Advanced Cancer Or Metastatic Cancer",
      "status": "TERMINATED",
      "last_update": "2026-06-09",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05358938",
      "title": "Exercise to Boost Response to Checkpoint Blockade Immunotherapy",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-09-15",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05429866",
      "title": "Immunological Variables Associated to ICI Toxicity in Cancer Patients",
      "status": "UNKNOWN",
      "last_update": "2023-03-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05864144",
      "title": "A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2026-09-02",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "CONTUSUGENE LADENOVEC": {
    "n": 1,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT03544723",
      "title": "Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors.",
      "status": "UNKNOWN",
      "last_update": "2020-06-09",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "COSIBELIMAB": {
    "n": 1,
    "n_observational": 0,
    "n_active": 1,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT03212404",
      "title": "Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-02-03",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "DURVALUMAB": {
    "n": 7,
    "n_observational": 0,
    "n_active": 1,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT02643303",
      "title": "A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible Cancers",
      "status": "COMPLETED",
      "last_update": "2022-12-02",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02890368",
      "title": "Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis Fungoides",
      "status": "TERMINATED",
      "last_update": "2023-04-05",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03228667",
      "title": "QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-01-14",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03544723",
      "title": "Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors.",
      "status": "UNKNOWN",
      "last_update": "2020-06-09",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04902040",
      "title": "Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies",
      "status": "TERMINATED",
      "last_update": "2026-04-30",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05429866",
      "title": "Immunological Variables Associated to ICI Toxicity in Cancer Patients",
      "status": "UNKNOWN",
      "last_update": "2023-03-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06939036",
      "title": "Study of 225Ac-SS0110 in Subjects With ES-SCLC or MCC (SANTANA-225 )",
      "status": "TERMINATED",
      "last_update": "2026-02-05",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "LORVOTUZUMAB MERTANSINE": {
    "n": 1,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT00346385",
      "title": "BB-10901 in Treating Patients With Relapsed or Refractory Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2015-03-26",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "NAVTEMADLIN": {
    "n": 1,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT03787602",
      "title": "Navtemadlin (KRT-232) With or Without Anti-PD-1/Anti-PD-L1 for the Treatment of Patients With Merkel Cell Carcinoma",
      "status": "UNKNOWN",
      "last_update": "2023-03-02",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "NIVOLUMAB": {
    "n": 23,
    "n_observational": 0,
    "n_active": 11,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT05076760",
      "title": "MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2026-06-11",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05267626",
      "title": "Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2R\u03b1 Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer",
      "status": "RECRUITING",
      "last_update": "2026-07-30",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05896839",
      "title": "Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer",
      "status": "RECRUITING",
      "last_update": "2026-08-31",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06047379",
      "title": "Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis",
      "status": "RECRUITING",
      "last_update": "2026-09-15",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06151236",
      "title": "Neoadjuvant Nivolumab and Relatlimab in Merkel Cell Carcinoma",
      "status": "RECRUITING",
      "last_update": "2026-02-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02196961",
      "title": "Adjuvant Therapy of Completely Resected Merkel Cell Carcinoma With Immune Checkpoint Blocking Antibodies vs Observation",
      "status": "COMPLETED",
      "last_update": "2025-04-09",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02890368",
      "title": "Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis Fungoides",
      "status": "TERMINATED",
      "last_update": "2023-04-05",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02978625",
      "title": "Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03071406",
      "title": "Randomized Study of Nivolumab+Ipilimumab+/- SBRT for Metastatic Merkel Cell Carcinoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-03-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03126110",
      "title": "Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies",
      "status": "COMPLETED",
      "last_update": "2025-08-14",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03228667",
      "title": "QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-01-14",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03241173",
      "title": "A Study Exploring the Safety and Efficacy of INCAGN01949 in Combination With Immune Therapies in Advanced or Metastatic Malignancies",
      "status": "COMPLETED",
      "last_update": "2022-09-27",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03435640",
      "title": "REVEAL Study of NKTR-262 in Combination With NKTR-214 and Nivolumab in Patients With Locally Advanced / Metastatic Solid Tumor Malignancies",
      "status": "TERMINATED",
      "last_update": "2023-03-08",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03544723",
      "title": "Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors.",
      "status": "UNKNOWN",
      "last_update": "2020-06-09",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03798639",
      "title": "Nivolumab and Radiation Therapy or Ipilimumab as Adjuvant Therapy in Treating Patients With Merkel Cell Cancer",
      "status": "COMPLETED",
      "last_update": "2024-04-12",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03816332",
      "title": "Tacrolimus, Nivolumab, and Ipilimumab in Treating Kidney Transplant Recipients With Selected Unresectable or Metastatic Cancers",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-31",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03841110",
      "title": "FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2023-05-01",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04157985",
      "title": "Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2025-12-11",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04902040",
      "title": "Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies",
      "status": "TERMINATED",
      "last_update": "2026-04-30",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05069935",
      "title": "FT538 in Combination With Monoclonal Antibodies in Advanced Solid Tumors",
      "status": "TERMINATED",
      "last_update": "2023-09-21",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05358938",
      "title": "Exercise to Boost Response to Checkpoint Blockade Immunotherapy",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-09-15",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05429866",
      "title": "Immunological Variables Associated to ICI Toxicity in Cancer Patients",
      "status": "UNKNOWN",
      "last_update": "2023-03-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07576725",
      "title": "Low Dose, Reduced Frequency Nivolumab for the Treatment of Unresectable or Metastatic Cancer, AFFORD IO Trial",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-05-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "PEMBROLIZUMAB": {
    "n": 37,
    "n_observational": 0,
    "n_active": 16,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT05086692",
      "title": "A Beta-only IL-2 ImmunoTherapY Study",
      "status": "RECRUITING",
      "last_update": "2025-07-09",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05269381",
      "title": "Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2026-08-20",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05496036",
      "title": "Neoadjuvant PD-1 Blockade in Resectable Merkel Cell Carcinoma",
      "status": "RECRUITING",
      "last_update": "2026-02-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05583708",
      "title": "Phase II Study of Peptide Receptor Radionuclide Therapy in Combination With Immunotherapy for Patients With Merkel Cell Cancer",
      "status": "RECRUITING",
      "last_update": "2026-04-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05859074",
      "title": "A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer",
      "status": "RECRUITING",
      "last_update": "2026-08-12",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06047379",
      "title": "Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis",
      "status": "RECRUITING",
      "last_update": "2026-09-15",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06940440",
      "title": "IFx-Hu2.0 As An Adjunctive Therapy To Pembrolizumab In Advanced Or Metastatic Merkel Cell Carcinoma (MCC)",
      "status": "RECRUITING",
      "last_update": "2025-10-15",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06947928",
      "title": "Placebo-Controlled Trial of IFx-Hu2.0 Followed By Pembrolizumab In Checkpoint Inhibitor Na\u00efve Participants With Advanced Or Metastatic Merkel Cell Carcinoma",
      "status": "RECRUITING",
      "last_update": "2026-04-17",
      "phase": "PHASE2/PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07302347",
      "title": "A Study of Pembrolizumab in Japanese Pediatric Participants With Solid Tumors or Lymphomas and Japanese Adult Participants With Merkel Cell Carcinoma (MK-3475-G21/KEYNOTE-G21)",
      "status": "RECRUITING",
      "last_update": "2026-07-13",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07749586",
      "title": "A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2026-08-06",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02267603",
      "title": "Pembrolizumab in Treating Patients With Advanced Merkel Cell Cancer",
      "status": "COMPLETED",
      "last_update": "2023-07-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02635672",
      "title": "Phase I Dose Escalation Study for VIP152 in Patients With Advanced Cancer",
      "status": "COMPLETED",
      "last_update": "2024-11-15",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02890368",
      "title": "Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis Fungoides",
      "status": "TERMINATED",
      "last_update": "2023-04-05",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03228667",
      "title": "QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-01-14",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03236935",
      "title": "Phase Ib of L-NMMA and Pembrolizumab",
      "status": "COMPLETED",
      "last_update": "2026-04-09",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03277352",
      "title": "INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies",
      "status": "TERMINATED",
      "last_update": "2021-07-22",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03304639",
      "title": "Testing the Addition of Radiation Therapy to Immunotherapy for Merkel Cell Carcinoma",
      "status": "COMPLETED",
      "last_update": "2026-08-25",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03544723",
      "title": "Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors.",
      "status": "UNKNOWN",
      "last_update": "2020-06-09",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03684785",
      "title": "Intratumoral Cavrotolimod Combined With Pembrolizumab or Cemiplimab in Patients With Merkel Cell Carcinoma, Cutaneous Squamous Cell Carcinoma, or Other Advanced Solid Tumors",
      "status": "TERMINATED",
      "last_update": "2022-04-07",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03712605",
      "title": "Testing Pembrolizumab Versus Observation in Patients With Merkel Cell Carcinoma After Surgery, STAMP Trial",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-04",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03747484",
      "title": "Gene-Modified Immune Cells (FH-MCVA2TCR) in Treating Patients With Metastatic or Unresectable Merkel Cell Cancer",
      "status": "TERMINATED",
      "last_update": "2025-03-06",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03783078",
      "title": "Pembrolizumab (MK-3475) as First-line Therapy for Advanced Merkel Cell Carcinoma (MK-3475-913)",
      "status": "COMPLETED",
      "last_update": "2025-05-28",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03841110",
      "title": "FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2023-05-01",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03988647",
      "title": "Palliative RT & Anti-PD-1/PD-L1 Checkpoint Blockade in Metastatic Merkel Cell Carcinoma",
      "status": "TERMINATED",
      "last_update": "2021-08-09",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04116320",
      "title": "Focused Ultrasound Ablation and PD-1 Antibody Blockade in Advanced Solid Tumors",
      "status": "TERMINATED",
      "last_update": "2025-07-14",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04157985",
      "title": "Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2025-12-11",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04187872",
      "title": "LITT and Pembrolizumab in Recurrent Brain Metastasis",
      "status": "TERMINATED",
      "last_update": "2023-12-27",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04234113",
      "title": "Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors",
      "status": "TERMINATED",
      "last_update": "2026-03-27",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04590781",
      "title": "Safety and Efficacy of XmAb18087 \u00b1 Pembrolizumab in Advanced Merkel Cell Carcinoma or Extensive-stage Small Cell Lung Cancer",
      "status": "TERMINATED",
      "last_update": "2023-04-20",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04616248",
      "title": "In Situ Immunomodulation With CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients w/ Unresectable and Metastatic Solid Tumors",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-06-18",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04725331",
      "title": "A Clinical Trial Assessing BT-001 Alone and in Combination With Pembrolizumab in Metastatic or Advanced Solid Tumors",
      "status": "TERMINATED",
      "last_update": "2025-11-21",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04869137",
      "title": "Neoadjuvant Lenvatinib Plus Pembrolizumab in Merkel Cell Carcinoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-04-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04902040",
      "title": "Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies",
      "status": "TERMINATED",
      "last_update": "2026-04-30",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05069935",
      "title": "FT538 in Combination With Monoclonal Antibodies in Advanced Solid Tumors",
      "status": "TERMINATED",
      "last_update": "2023-09-21",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05358938",
      "title": "Exercise to Boost Response to Checkpoint Blockade Immunotherapy",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-09-15",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06086288",
      "title": "Study of PembrolizumAb combiNeD With Cisplatin or carbOplatin and Etoposide in Treatment na\u00efve Advanced meRkel Cell cArcinoma (MCC)",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2023-10-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06939036",
      "title": "Study of 225Ac-SS0110 in Subjects With ES-SCLC or MCC (SANTANA-225 )",
      "status": "TERMINATED",
      "last_update": "2026-02-05",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "RELATLIMAB": {
    "n": 2,
    "n_observational": 0,
    "n_active": 2,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT06151236",
      "title": "Neoadjuvant Nivolumab and Relatlimab in Merkel Cell Carcinoma",
      "status": "RECRUITING",
      "last_update": "2026-02-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05358938",
      "title": "Exercise to Boost Response to Checkpoint Blockade Immunotherapy",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-09-15",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "RETIFANLIMAB": {
    "n": 5,
    "n_observational": 0,
    "n_active": 3,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT03599713",
      "title": "A Study of INCMGA00012 in Metastatic Merkel Cell Carcinoma (POD1UM-201)",
      "status": "COMPLETED",
      "last_update": "2025-08-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05594290",
      "title": "Chemo-immunotherapy in Patients With Resectable Merkel Cell Carcinoma Prior to Surgery",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-01-14",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06056895",
      "title": "Triple Immune Checkpoint Inhibition for Advanced or Metastatic PD-(L)1 Refractory Merkel Cell Carcinoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06939036",
      "title": "Study of 225Ac-SS0110 in Subjects With ES-SCLC or MCC (SANTANA-225 )",
      "status": "TERMINATED",
      "last_update": "2026-02-05",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07472322",
      "title": "ASTX727 & Retifanlimab-dlwr for Advanced Merkel Cell After Progression on Anti-PD-(L)1",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-09-02",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "SASANLIMAB": {
    "n": 1,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT04458259",
      "title": "Study of PF-07265807 in Participants With Metastatic Solid Tumors.",
      "status": "TERMINATED",
      "last_update": "2026-06-04",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "ZIMBERELIMAB": {
    "n": 1,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT03629756",
      "title": "A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies",
      "status": "COMPLETED",
      "last_update": "2024-05-24",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     }
    ]
   }
  }
 }
}